Electrocore (ECOR) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Electrocore (ECOR) today and set a price target of $3.00. The company’s shares closed last Thursday at $2.26.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 35.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
Currently, the analyst consensus on Electrocore is a Strong Buy with an average price target of $3.50, a 64.3% upside from current levels. In a report released today, BTIG also upgraded the stock to Buy with a $3.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.64 and a one-year low of $0.32. Currently, Electrocore has an average volume of 5.43M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
Read More on ECOR: